SCHEDULE 13G: Nomura Holdings Discloses 5.2% Stake in Poseida Therapeutics

Nomura Holdings Inc. and its subsidiary Nomura Global Financial Products Inc. have disclosed a 5.2% beneficial ownership stake in Poseida Therapeutics, Inc., holding 5,115,015 shares of common stock.

Summary

• Nomura Holdings Inc. and Nomura Global Financial Products, Inc. (NGFP) have jointly filed a Schedule 13G, reporting beneficial ownership in Poseida Therapeutics, Inc.
• The reporting persons collectively beneficially own 5,115,015 shares of Poseida Therapeutics, Inc. Common Stock.
• This ownership represents 5.2% of the outstanding Common Stock of Poseida Therapeutics, Inc.
• The percentage is calculated based on 97,774,206 shares of Common Stock outstanding as of December 2, 2024, as reported in Poseida's Schedule 14D-9 filing on December 9, 2024.
• NGFP is a wholly owned subsidiary of Nomura Holdings, Inc., and both entities share voting and dispositive power over the reported shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a 13G filing is routine, the disclosure of a significant stake by a major financial institution like Nomura can be perceived positively as a vote of confidence in the issuer, Poseida Therapeutics. However, the filing itself contains no operational or financial news about the issuer.

Positives

• A significant institutional investor, Nomura Holdings, has taken a substantial 5.2% stake in Poseida Therapeutics, which can be viewed as a vote of confidence in the company.
• The acquisition of shares was stated to be in the ordinary course of business, indicating a passive investment rather than an attempt to influence control.

Future Outlook

NA

Management Comments

• Samir Patel, Managing Director of Nomura Holdings Inc., and Authorized Officer of Nomura Global Financial Products Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of the issuer.

Industry Context

This filing indicates a significant institutional investment in Poseida Therapeutics, Inc., a biotechnology company. Such disclosures are common in the financial industry as large investment firms manage diverse portfolios, and a 5% stake triggers mandatory reporting requirements. It reflects Nomura's investment strategy rather than a specific trend within the biotechnology sector itself, though it does highlight continued institutional interest in the company.

Related Party Transactions

• Nomura Global Financial Products, Inc. is a wholly owned subsidiary of Nomura Holdings, Inc., and their beneficial ownership is reported jointly.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional shareholder may influence investor perception and potentially stock trading activity.
• Company Management: Awareness of a new large, passive shareholder may be noted, but it does not imply direct influence on company operations or strategy given the nature of a 13G filing.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Nomura Holdings, Poseida Therapeutics, Equity Stake, Institutional Investment, Common Stock